Tagrisso’s first-quarter performance
In the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis and 92% on a CER (constant exchange rate) basis. According to AstraZeneca, Tagrisso is its top-selling medicine. The drug is approved in 83 countries as a second-line EGFR[1.epidermal growth factor receptor] T790M mutation-positive NSCLC[2.non-small cell lung cancer) treatment and in 67 countries as a first-line EGFR mutated NSCLC treatment.
Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
Tagrisso’s US revenue rose 76% YoY to $259 million in the first quarter. According to AstraZeneca, Tagrisso has been adopted by more than 60% of new first-line EGFR mutated NSCLC patients in the United States and has emerged as a standard of care. The drug accounts for more than 80% of first-line EGFR mutated NSCLC treated with TKI (tyrosine kinase inhibitor) therapy in the country.
In its first-quarter conference call, AstraZeneca stated that inventory reductions and unfavorable gross-to-net adjustments resulted in US Tagrisso sales falling sequentially in the first quarter. However, demand rose sequentially by a mid-single percentage.
Tagrisso’s European revenue rose 45% YoY to $100 million on a reported basis and 55% on a CER basis, mainly driven by higher diagnosis rates and demand for the drug in second-line EGFR T790M mutation-positive NSCLC. AstraZeneca reported in its first-quarter call that Tagrisso is being launched as a first-line EGFR mutated NSCLC treatment in Denmark, Italy, and France, where penetration is 35%–50%. AstraZeneca plans to launch the drug and secure reimbursement in other European markets in future quarters.